Medline (NASDAQ:MDLN) Given Consensus Rating of “Moderate Buy” by Analysts

Medline (NASDAQ:MDLN) has been given an average rating of “Moderate Buy” by the twenty-nine analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, twenty-two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $50.5385.

MDLN has been the subject of a number of research reports. Weiss Ratings downgraded shares of Medline from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, July 23rd. BTIG Research reaffirmed a “buy” rating and issued a $55.00 price target on shares of Medline in a report on Thursday, May 7th. BNP Paribas Exane reduced their price objective on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Deutsche Bank Aktiengesellschaft set a $42.00 target price on Medline in a research report on Thursday, May 7th. Finally, Sanford C. Bernstein cut their price target on Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th.

Insider Transactions at Medline

In other Medline news, insider Jessi L. Corcoran bought 5,000 shares of Medline stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the completion of the purchase, the insider directly owned 5,000 shares of the company’s stock, valued at approximately $170,750. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Douglas P. Golwas sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the sale, the insider directly owned 23,899 shares in the company, valued at approximately $878,766.23. This trade represents a 80.71% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.81% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medline

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mass General Brigham Inc bought a new position in shares of Medline in the fourth quarter worth $1,104,000. Sumitomo Mitsui Trust Group Inc. purchased a new stake in Medline during the 1st quarter worth about $1,177,000. Baillie Gifford & Co. bought a new position in Medline in the 4th quarter worth about $437,236,000. Massachusetts Financial Services Co. MA purchased a new position in Medline during the 4th quarter valued at about $429,544,000. Finally, UBS Group AG purchased a new position in Medline during the 4th quarter valued at about $54,707,000.

Medline Trading Down 2.4%

NASDAQ MDLN opened at $39.12 on Friday. The business’s fifty day moving average is $38.04 and its 200-day moving average is $41.93. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. The stock has a market capitalization of $51.39 billion and a price-to-earnings ratio of 122.25. Medline has a one year low of $32.81 and a one year high of $50.88.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. Medline’s quarterly revenue was up 10.7% on a year-over-year basis. Equities research analysts predict that Medline will post 1.49 EPS for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.